Taiho Oncology, Inc.
Matthew Johnson is an experienced professional in process chemistry, currently serving as Executive Director at Taiho Oncology, Inc. since January 2024. Prior roles include Executive Director of Process Chemistry at Astex Pharmaceuticals from March 2020 to January 2024, and Vice President of Chemical Development at Asymchem Group from March 2017 to February 2020. Additionally, Matthew held positions at Asymchem as Director of Chemical Development and as a Senior Research Scientist II at AMRI, where responsibilities included leading medicinal chemistry projects. Early career experience encompasses a senior chemist role at Biofocus and a postdoctoral position at Queen's University under Professor Victor Snieckus. Educational credentials include a postdoctoral fellowship at Queen's University in metallation and cross-coupling, and a Ph.D. and B.Sc. from the University of Birmingham focusing on combinatorial carbohydrate chemistry.
This person is not in any teams
This person is not in any offices
Taiho Oncology, Inc.
2 followers
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a world-class clinical development organization. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada. For more information, visit www.taihooncology.com